Diagnostic value of total serum/free prostate specific antigen and prostate cancer antigen-3 levels in prostate cancer

• Published in: American journal of clinical and experimental urology Vol. 11; no. 5; pp. 414 - 419
• Main Authors: Yazdani, Mohammad, Saberi, Narjes, Baradaran, Azar, Mohajeri, Zahra
• Format: Journal Article
• Language: English
• Published: e-Century Publishing Corporation 01.01.2023
• Subjects: Original
• ISSN: 2330-1910; 2330-1910

BACKGROUNDThe purpose of this study was to compare serum total and free prostate specific antigen (PSA) levels and serum prostate cancer antigen-3 (PCA3) levels in patients with prostate cancer in 2018 and 2019.METHODSThis research was a prospective case-control study. The case group included all patients with suspected prostate cancer, and the control group included individuals without prostate disease who were referred to Ali Asghar and Nour Hospital in Isfahan, Iran, from October 2018 to October 2020. The serum total PSA, free PSA, and PCA3 levels in both groups were measured using the ELISA method with standard kits and compared between the groups.RESULTSThe two groups were matched in terms of age and body mass index (BMI). The results showed that the mean free PSA level in the control group was significantly higher than that in the case group (P<0.05). Conversely, the mean total PSA level in the case group was significantly higher than that in the control group (P<0.05). However, no significant difference was observed in the mean PCA3 levels between the case and control groups. In addition, the total PSA variable with a cutoff of ≤3.14 exhibited 93% sensitivity and 82% specificity, demonstrating the highest diagnostic accuracy in distinguishing between prostate cancer and healthy individuals. Similarly, the PCA3 value with a cutoff of ≤3.5 had a sensitivity and specificity of 70% and 72%, respectively.CONCLUSIONOverall, the study results indicated that total PSA and PCA3 levels have higher diagnostic accuracy in distinguishing patients with suspected prostate cancer from healthy individuals.